Detalles de la búsqueda
1.
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
BMC Med Res Methodol
; 22(1): 215, 2022 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35931967
2.
Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
PLoS One
; 19(5): e0302486, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38743917
3.
A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia.
PLoS One
; 17(4): e0266824, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35427376
4.
Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia.
J Health Econ Outcomes Res
; 8(1): 42-50, 2021 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33987450
5.
Cost-effectiveness of overactive bladder treatments: from the US payer perspective.
J Comp Eff Res
; 8(1): 61-71, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30511584
6.
Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population.
J Manag Care Spec Pharm
; 23(4): 446-452, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28345434
7.
Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model.
Diabetes Technol Ther
; 8(2): 219-36, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16734551
8.
OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
Eur J Health Econ
; 17(7): 911-21, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26482712
9.
Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.
Pharmacoeconomics
; 33(4): 381-93, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25526842
10.
Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy.
Expert Rev Anticancer Ther
; 15(1): 121-8, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25248391
11.
Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain.
Clinicoecon Outcomes Res
; 4: 299-305, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23071397
Resultados
1 -
11
de 11
1
Próxima >
>>